Cite
A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival.
MLA
Barrón-Gallardo, Carlos A., et al. “A Gene Expression Signature in HER2+ Breast Cancer Patients Related to Neoadjuvant Chemotherapy Resistance, Overall Survival, and Disease-Free Survival.” Frontiers in Genetics, vol. 13, Oct. 2022, pp. 1–14. EBSCOhost, https://doi.org/10.3389/fgene.2022.991706.
APA
Barrón-Gallardo, C. A., Garcia-Chagollán, M., Morán-Mendoza, A. J., Delgadillo-Cristerna, R., Martínez-Silva, M. G., Villaseñor-García, M. M., Aguilar-Lemarroy, A., & Jave-Suárez, L. F. (2022). A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. Frontiers in Genetics, 13, 1–14. https://doi.org/10.3389/fgene.2022.991706
Chicago
Barrón-Gallardo, Carlos A., Mariel Garcia-Chagollán, Andres J. Morán-Mendoza, Raul Delgadillo-Cristerna, María G. Martínez-Silva, María M. Villaseñor-García, Adriana Aguilar-Lemarroy, and Luis F. Jave-Suárez. 2022. “A Gene Expression Signature in HER2+ Breast Cancer Patients Related to Neoadjuvant Chemotherapy Resistance, Overall Survival, and Disease-Free Survival.” Frontiers in Genetics 13 (October): 1–14. doi:10.3389/fgene.2022.991706.